Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L R Hoes

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Cancer Chemotherapy and Pharmacology|May 22, 2022
Efficacy and toxicity of vemurafenib and cobimetinib in relation to plasma concentrations, after administration via feeding tube in patients with BRAF-mutated thyroid cancer: a case series and review of literatureJ M van Berge Henegouwen, H van der Wijngaart, L J Zeverijn, et al.
ESMO Open|January 8, 2025
The pathway alteration load is a pan-cancer determinant of outcome of targeted therapies: results from the Drug Rediscovery Protocol (DRUP)K Verkerk, L J Zeverijn, J van de Haar, et al.
ESMO Open|April 22, 2021
Prospective experimental treatment of colorectal cancer patients based on organoid drug responsesS N Ooft, F Weeber, L Schipper, et al.
European Journal of Cancer (Oxford, England : 1990)|June 18, 2022
Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancerJ M van Berge Henegouwen, M Jebbink, L R Hoes, et al.
Nature|October 2, 2019
The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugsD L van der Velden, L R Hoes, H van der Wijngaart, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Cancer Chemotherapy and Pharmacology|May 22, 2022
Efficacy and toxicity of vemurafenib and cobimetinib in relation to plasma concentrations, after administration via feeding tube in patients with BRAF-mutated thyroid cancer: a case series and review of literatureJ M van Berge Henegouwen, H van der Wijngaart, L J Zeverijn, et al.
ESMO Open|January 8, 2025
The pathway alteration load is a pan-cancer determinant of outcome of targeted therapies: results from the Drug Rediscovery Protocol (DRUP)K Verkerk, L J Zeverijn, J van de Haar, et al.
ESMO Open|April 22, 2021
Prospective experimental treatment of colorectal cancer patients based on organoid drug responsesS N Ooft, F Weeber, L Schipper, et al.
European Journal of Cancer (Oxford, England : 1990)|June 18, 2022
Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancerJ M van Berge Henegouwen, M Jebbink, L R Hoes, et al.
Nature|October 2, 2019
The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugsD L van der Velden, L R Hoes, H van der Wijngaart, et al.
Pageof 1